Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 2:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 632 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Control gel Clear all
Recruiting Phase 2 Interventional

Pathways Relating Amnestic MCI to a Mild Traumatic Brain Injury History

NCT05446584
View directory record Official record
Conditions
Mild Cognitive Impairment, Amnestic Mild Cognitive Disorder, Amnestic Mild Cognitive Impairment, Mild Traumatic Brain Injury, Concussion, Brain
Interventions
High Definition Transcranial Direct Current Stimulation
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
55 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 5, 2026, 2:21 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC

NCT04155190
View directory record Official record
Conditions
Recurrent Basal Cell Carcinoma
Interventions
Patidegib Topical Gel, 2%, Patidegib Topical Gel, Vehicle
Drug
Lead sponsor
Sol-Gel Technologies, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
14
States / cities
Apple Valley, California • Colton, California • Fremont, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 5, 2026, 2:21 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of a Test Naproxen Sodium 220mg Tablet in Postoperative Dental Pain

NCT03566979
View directory record Official record
Conditions
Post-operative Dental Pain
Interventions
Test naproxen sodium tablet, Commercial naproxen sodium tablet, Commercial naproxen sodium liquid gels capsule, Placebo tablet
Drug
Lead sponsor
Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division
Industry
Eligibility
17 Years to 50 Years
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 8, 2020 · Synced Sep 5, 2026, 2:21 AM EDT
Completed Phase 4 Interventional Results available

Diclofenac Sodium Topical Gel to Reduce Injection Site Discomfort in Patients Taking Glatiramer Acetate

NCT01454791
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
diclofenac sodium topical gel, Placebo
Drug · Other
Lead sponsor
Brown, Theodore R., M.D., MPH
Individual
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Kirkland, Washington
Source: ClinicalTrials.gov public record
Updated Mar 4, 2015 · Synced Sep 5, 2026, 2:21 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of TBS-2 Testosterone Gel in Women With Acquired Female Orgasmic Disorder

NCT01607658
View directory record Official record
Conditions
Female Orgasmic Disorder
Interventions
Placebo, Low dose TBS-2, Medium dose TBS-2, High dose TBS-2
Drug
Lead sponsor
Acerus Pharmaceuticals Corporation
Industry
Eligibility
18 Years and older · Female only
Enrollment
253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
43
States / cities
Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2018 · Synced Sep 5, 2026, 2:21 AM EDT
Terminated Phase 4 Interventional Results available

Acthar Gel for Multiple Sclerosis That Keeps Getting Better and Worse (RRMS)

NCT03126760
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Acthar Gel, Placebo
Drug
Lead sponsor
Mallinckrodt ARD LLC
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
22
States / cities
Palo Alto, California • Fort Collins, Colorado • Bradenton, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2021 · Synced Sep 5, 2026, 2:21 AM EDT
Terminated Phase 2 Interventional Results available

Development of A Novel Anti-Hyperglycemic Agent

NCT00878605
View directory record Official record
Conditions
Diabetes
Interventions
Cyclo-Z, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
West Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 13, 2018 · Synced Sep 5, 2026, 2:21 AM EDT
Completed Phase 3 Interventional

A Therapeutic Equivalence Study of Two Metronidazole Gel 1% Topical Treatments of Rosacea

NCT02393937
View directory record Official record
Conditions
Papulopustular Rosacea, Erythematotelangiectatic Rosacea
Interventions
Reference: Metronidazole Gel 1%, Test: Metronidazole Gel 1%, Placebo Gel
Drug
Lead sponsor
bioRASI, LLC
Industry
Eligibility
18 Years and older
Enrollment
963 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
27
States / cities
Los Angeles, California • San Diego, California • Boca Raton, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Sep 5, 2026, 2:21 AM EDT
Not listed Phase 2 Interventional

Topical Minocycline Gel for Inflammatory Lesions of Papulopustular Rosacea

NCT03667222
View directory record Official record
Conditions
Papulopustular Rosacea
Interventions
minocycline topical gel, topical gel vehicle
Drug
Lead sponsor
BioPharmX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
12
States / cities
Anaheim Hills, California • Miami, Florida • Miramar, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Sep 5, 2026, 2:21 AM EDT
Completed Phase 2 Interventional

COL-1077 (Lidocaine Bioadhesive Gel, 10%) in Women Undergoing Transvaginal Pipelle-Directed Endometrial Biopsy

NCT02465320
View directory record Official record
Conditions
Endometrial Biopsy
Interventions
COL-1077, Placebo
Drug
Lead sponsor
Juniper Pharmaceuticals, Inc.
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
23
States / cities
Norwalk, California • Colorado Springs, Colorado • Lakewood, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Sep 5, 2026, 2:21 AM EDT
Completed Phase 3 Interventional

Trial of Dapsone 5.0% Gel in the Treatment of Acne Vulgaris

NCT02865005
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Dapsone 5.0% Gel (SEEGPharm), Placebo, Dapsone 5.0% Gel (Allergan)
Drug · Other
Lead sponsor
Seegpharm S.A.
Industry
Eligibility
12 Years to 40 Years
Enrollment
2,361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
35
States / cities
Encino, California • Fullerton, California • La Mesa, California + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2016 · Synced Sep 5, 2026, 2:21 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Non-invasive Stimulation of the Glymphatic System for Slowing Cognitive Decline

NCT07044596
View directory record Official record
Conditions
Mild Traumatic Brain Injury, Post Concussion Syndrome
Interventions
Functional near-infrared spectroscopy (fNIRS), V1 stimulation electrodes, Magnetic Resonance Imaging (MRI), MAGNUS scanner
Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
20 Years to 85 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 5, 2026, 2:21 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Natesto Testosterone Nasal Gel for Hypogonadal Men

NCT05484167
View directory record Official record
Conditions
Erectile Dysfunction, Sexual Dysfunction
Interventions
Natesto Nasal Product, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 64 Years · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Sep 5, 2026, 2:21 AM EDT
Completed Not applicable Interventional Results available

Postoperative Subtenons Anesthesia for Postoperative Pain in Pediatric Strabismus Surgery

NCT01812044
View directory record Official record
Conditions
Strabismus
Interventions
subtenons anesthetic - preservative-free bupivacaine 0.75%, topical anesthetic - 0.5 cc of lidocaine 3.5% ophthalmic gel, topical control - 0.5 cc of Hypromellose 0.3% gel, subtenons control - 0.5 cc of Normal Saline
Drug
Lead sponsor
Duke University
Other
Eligibility
1 Year to 7 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 25, 2016 · Synced Sep 5, 2026, 2:21 AM EDT
Recruiting Phase 2 Interventional

FAST for DM - Fatty Acid Supplementation Trial (FAST) for Dermatomyositis (DM)

NCT07111065
View directory record Official record
Conditions
Dermatomyositis (DM), Juvenile Dermatomyositis (JDM)
Interventions
FISH OIL 500MG OMEGA-3 SOFT GEL MINIS, Placebo
Dietary Supplement
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
18 Years to 60 Years
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 5, 2026, 2:21 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Randomized Control Trial Comparing Single vs. Multiple Application of Lidocaine Analgesia Prior to Urethral Catheterization Procedures

NCT00142064
View directory record Official record
Conditions
Urinary Tract Infection, Kidney Diseases, Ureteral Diseases, Ureteral Obstruction
Interventions
observed levels of pain
Behavioral
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
2 Months to 7 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 17, 2007 · Synced Sep 5, 2026, 2:21 AM EDT
Completed Phase 2 Interventional

Study of DHT-Gel to Treat the Symptoms of Low Testosterone in Men 55-80

NCT00163566
View directory record Official record
Conditions
Hypogonadism, Late Onset Hypogonadism, Low Testosterone
Interventions
Dihydrotestosterone (0.7%) in hydroalcoholic gel
Drug
Lead sponsor
ASCEND Therapeutics
Industry
Eligibility
55 Years to 80 Years · Male only
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
16
States / cities
Phoenix, Arizona • Torrance, California • Gainesville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2022 · Synced Sep 5, 2026, 2:21 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate Safety and Effectiveness of NOA VOLUME Injectable Gel in Adult Participants Compared to JUVÉDERM VOLUMA XC for Improvement of Mid-Face Volume

NCT06734351
View directory record Official record
Conditions
Mid Face Volume Deficit
Interventions
NOA VOLUME, VOLUMA XC
Device
Lead sponsor
AbbVie
Industry
Eligibility
22 Years and older
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
15
States / cities
Birmingham, Alabama • Glendale, Arizona • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 5, 2026, 2:21 AM EDT
Not yet recruiting Phase 4 Interventional

PLEASURE (Pleasing Lovers, Efficacy, Arousal, Satisfaction, and Uptake Research on Eroxon)

NCT07636161
View directory record Official record
Conditions
Type 2 Diabetes, Type 2 Diabetes (T2DM)
Interventions
Eroxon®, tadalafil
Device · Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 40 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 5, 2026, 2:21 AM EDT
Not yet recruiting Phase 2 Interventional

Clinical Study to Evaluate the Safety and the Efficacy of EscharEx Drug Product (EX-03 Formulation) and Its Placebo Compared to Collagenase, Non-surgical Standard of Care, in Patients With Venous Leg Ulcers

NCT06690177
View directory record Official record
Conditions
Venus Leg Ulcers
Interventions
EscharEx (EX-03), Placebo (Gel vehicle)
Drug
Lead sponsor
MediWound Ltd
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Carlsbad, California
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Sep 5, 2026, 2:21 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Papulopustular Rosacea Study

NCT01493687
View directory record Official record
Conditions
Papulopustular Rosacea (PPR)
Interventions
CD5024, Azelaic acid 15% Gel
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
683 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
40
States / cities
Birmingham, Alabama • Rogers, Arkansas • Los Angeles, California + 36 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Sep 5, 2026, 2:21 AM EDT
Terminated Phase 3 Interventional Results available

Trial of 4-Hydroxytamoxifen (4-OHT) Gel in Women Aimed at Reducing Dense Breast Tissue

NCT03199963
View directory record Official record
Conditions
Mammographic Breast Density
Interventions
4-OH tamoxifen, Placebo
Drug
Lead sponsor
BHR Pharma, LLC
Industry
Eligibility
35 Years to 75 Years · Female only
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
17
States / cities
Mesa, Arizona • Tucson, Arizona • Beverly Hills, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Sep 5, 2026, 2:21 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study Comparing the Safety and Efficacy of IDP-120 Gel and IDP-120 Vehicle Gel in the Treatment of Acne Vulgaris

NCT03664739
View directory record Official record
Conditions
Acne Vulgaris
Interventions
IDP-120 Gel, IDp-120 Vehicle Gel
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
9 Years and older
Enrollment
608 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
25
States / cities
Mobile, Alabama • Hot Springs, Arkansas • Beverly Hills, California + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2023 · Synced Sep 5, 2026, 2:21 AM EDT
Completed Phase 2 Interventional Results available

A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL)

NCT03292406
View directory record Official record
Conditions
Cutaneous T Cell Lymphoma
Interventions
Placebo, CD11301 0.03%, CD11301 0.06%
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
11
States / cities
Orange, California • Palo Alto, California • Farmington, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2021 · Synced Sep 5, 2026, 2:21 AM EDT